Demographics and clinical characteristics
| All patients 56 women 61 pregnancies 202 visits | Subgroup for PK model 22 women 22 pregnancies 55 visits | |
| N (%) or median (IQR) | N (%) or median (IQR) | |
| Age (years) | 31 (27.5–34.3) | 32 (28.9–34.6) |
| Race | ||
| White | 29 (47.5%) | 9 (40.9%) |
| Black | 30 (49.2%) | 12 (54.5%) |
| Other | 2 (3.3%) | 1 (4.5%) |
| Weight (kg), visit* | 79.4 (66.7–96.3) | 81.1 (65.7–100) |
| Missing weight, visit | 5 (2.5%) | 2 (3.6%) |
| Active LN in last 3 years | 9 (14.8%) | 2 (9.1%) |
| Serum creatinine (mg/dL), visit* | 0.6 (0.5–0.8) | 0.7 (0.6–0.8) |
| Missing serum creatinine, visit* | 24 (11.9%) | 7 (12.7%) |
| Disease activity (PGA) | 0.33 (0–0.75) | 0.25 (0.05–0.67) |
| Disease activity (PGA), visit* | 0.39 (0–0.63) | 0.18 (0–0.62) |
| Prednisone use, visit* | 68 (33.7%) | 14 (25.5%) |
| Prednisone dosage (mg), visit* | 10 (5–20) | 7.5 (5–13.4) |
| Azathioprine use, visit* | 74 (36.6%) | 17 (30.9%) |
| HCQ daily dosage (mg), visit* | ||
| 400 | 157 (77.7%) | 41 (74.5%) |
| 200 | 18 (8.9%) | 5 (9.1%) |
| Other | 27 (13.4%) | 9 (16.4%) |
| HCQ dosing interval (hour), visit* | ||
| 24 | 141 (69.8%) | 39 (70.9%) |
| 12 | 61 (30.2%) | 16 (29.1%) |
*'Visit’ represents the value across all study visits; whereas the data otherwise represent values averaged across all time points for each unique pregnancy. Weight and creatinine represent observed value before imputing missing data.
HCQ, hydroxychloroquine; LN, lupus nephritis; PGA, Physician Global Assessment; PK, pharmacokinetic.